Representatives Probe CMS for Further Detail on New CAR-T Therapy Payment Agreement – AJMC.com Managed Markets Network
|
Representatives Probe CMS for Further Detail on New CAR–T Therapy Payment Agreement
AJMC.com Managed Markets Network After CMS and Novartis devised an outcomes-based payment approach for the new chimeric antigen receptor (CAR)-T treatment tisagenlecleucel (Kymriah), a group of representatives are requesting more information on the specifics of the agreement. |
